Although CCR2 K/O in breast cancer cells reduced tumor cell growth and recruitment of antiinflammatory protumorigenic macrophages (58), attempts to neutralize MCP-1 (CNTO888) and CCR2 (MLN1202) led only to transient and unpredictable anticancer activities in preclinical and clinical studies (NCT01204996, NCT01015560) (59). The gene discussed is CCR2; the disease is neoplasm.